Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Circassia Pharmaceuticals Plc LSE:CIR London Ordinary Share GB00BJVD3B28 ORD 0.08P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.05p -0.18% 28.05p 27.80p 28.30p 28.70p 27.50p 28.20p 154,242 16:35:17
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 48.3 -55.8 -34.0 - 105.15

Circassia Pharmaceuticals Plc FDA website posts Duaklir NDA approval

29/03/2019 3:58pm

UK Regulatory (RNS & others)


Circassia Pharmaceuticals (LSE:CIR)
Historical Stock Chart

2 Months : From Mar 2019 to May 2019

Click Here for more Circassia Pharmaceuticals Charts.

TIDMCIR

RNS Number : 5475U

Circassia Pharmaceuticals Plc

29 March 2019

Circassia Notes FDA Website Posting of Duaklir(R) in Approvals Section

Oxford, UK - 29 March 2019: Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), notes the US Food and Drug Administration (FDA) website includes Duaklir(R) as an FDA approved drug product with an action date of 29 March 2019. Circassia and AstraZeneca are seeking confirmation from FDA and intend to update the market as soon as possible with further details.

Contacts

Circassia

Steve Harris, Chief Executive Officer Tel: +44 (0) 1865 405 560

Julien Cotta, Chief Financial Officer

Rob Budge, Corporate Communications

Peel Hunt (Nominated Adviser and Joint Broker)

James Steel / Dr Christopher Golden Tel: +44 (0) 20 7418 8900

Numis Securities (Joint Broker)

James Black / Freddie Barnfield Tel: +44 (0) 20 7260 1000

FTI Consulting

Simon Conway / George Kendrick Tel: +44 (0) 20 3727 1000

About Circassia

Circassia is a world-class specialty pharmaceutical business focused on respiratory disease. The Company sells its novel, market-leading NIOX(R) asthma management products directly to specialists in the United States, United Kingdom, China and Germany, and in a wide range of other countries through its network of partners. In the United States, Circassia has a commercial collaboration with AstraZeneca in which it has the commercial rights to chronic obstructive pulmonary disease (COPD) treatments Tudorza(R) and Duaklir(R). Circassia also has the US and Chinese commercial rights to the late-stage ventilator-compatible nitric oxide product AirNOvent. For more information please visit www.circassia.com.

Forward-looking statements

This press release contains certain projections and other forward-looking statements with respect to the financial condition, results of operations, businesses and prospects of Circassia. The use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target" or "believe" and similar expressions (or the negatives thereof) are generally intended to identify forward-looking statements. These statements are based on current expectations and involve risk and uncertainty because they relate to events and depend upon circumstances that may or may not occur in the future. There are a number of factors that could cause actual results or developments to differ materially from those expressed or implied by these forward-looking statements. Any of the assumptions underlying these forward-looking statements could prove inaccurate or incorrect and therefore any results contemplated in the forward-looking statements may not actually be achieved. Nothing contained in this press release should be construed as a profit forecast or profit estimate. Investors or other recipients are cautioned not to place undue reliance on any forward-looking statements contained herein. Circassia undertakes no obligation to update or revise (publicly or otherwise) any forward-looking statement, whether as a result of new information, future events or other circumstances.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCPGUQAWUPBGAB

(END) Dow Jones Newswires

March 29, 2019 11:58 ET (15:58 GMT)

1 Year Circassia Pharmaceuticals Chart

1 Year Circassia Pharmaceuticals Chart

1 Month Circassia Pharmaceuticals Chart

1 Month Circassia Pharmaceuticals Chart
Your Recent History
LSE
CIR
Circassia ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20190519 08:50:42